Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 3;8(4):649.
doi: 10.3390/vaccines8040649.

COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response

Swati Jain  1 , Himanshu Batra  1 , Poonam Yadav  2 , Subhash Chand  3
Affiliations
Review

COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response

Swati Jain et al. Vaccines (Basel). .

Abstract

With a death toll of over one million worldwide, the COVID-19 pandemic caused by SARS-CoV-2 has become the most devastating humanitarian catastrophe in recent decades. The fear of acquiring infection and spreading to vulnerable people has severely impacted society's socio-economic status. To put an end to this growing number of infections and deaths as well as to switch from restricted to everyday living, an effective vaccine is desperately needed. As a result, enormous efforts have been made globally to develop numerous vaccine candidates in a matter of months. Currently, over 30 vaccine candidates are under assessment in clinical trials, with several undergoing preclinical studies. Here, we reviewed the major vaccine candidates based on the specific vaccine platform utilized to develop them. We also discussed the immune responses generated by these candidates in humans and preclinical models to determine vaccine safety, immunogenicity, and efficacy. Finally, immune responses induced in recovered COVID-19 patients and their possible vaccine development implications were also briefly reviewed.

Keywords: COVID-19; SARS-CoV-2; T-cell responses; convalescent patients; neutralizing antibodies; vaccine development; vaccine platforms; vaccine response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structural features of SARS-CoV-2. Spike (S) glycoprotein, the membrane (M) protein, and envelope (E) protein are embedded in the viral envelope. The RNA genome is complexed with the nucleocapsid (N) protein. Virus spike trimer is enlarged to depict its key subunits (S1 and S2) and N-terminal domains (NTD) and C-terminal domains (CTD) in the S1 subunit encompassing receptor-binding domain (RBD). S protein targets the host cell receptor, ACE2, through RBD in S1 subunit (Created with Biorender.com).
Figure 2
Figure 2
Graphical representation of the vaccine candidates with respect to their clinical stages of development. The number of candidates on the x axis are compared for each of the major vaccine platforms shown on the y axis. The clinical stage for the vaccine candidates in each platform is depicted by color-coded legends on the right of the graph. The graph is constructed based on the data obtained from the World Health Organization; draft landscape of COVID-19 candidate vaccines and Coronavirus Vaccine tracker. VLPs-virus-like particles, RNA-ribonucleic acid, DNA-deoxyribonucleic acid.
Figure 3
Figure 3
Different vaccine platforms for the COVID-19 vaccine. Left; viral and non-viral vaccine delivery platforms are shown. Right; antigen induced activation of antigen-presenting cells (APCs); a nexus of innate and adaptive immune arms activating T-cell and B-cell immunity by fundamental immunological pathways are represented to show how vaccine-elicited immune responses lead to the clearance of infection. (Created with Biorender.com).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Malik Y.A. Properties of Coronavirus and SARS-CoV-2. Malays. J. Pathol. 2020;42:3–11. - PubMed
    1. Xiao K., Zhai J., Feng Y., Zhou N., Zhang X., Zou J.-J., Li N., Guo Y., Li X., Shen X., et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nat. Cell Biol. 2020;583:286–289. doi: 10.1038/s41586-020-2313-x. - DOI - PubMed
    1. Rehman S.U., Shafique L., Ihsan A., Liu Q. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2. Pathogens. 2020;9:240. doi: 10.3390/pathogens9030240. - DOI - PMC - PubMed
    1. Azkur A.K., Akdis M., Azkur D., Sokolowska M., Van De Veen W., Brüggen M., O’Mahony L., Gao Y., Nadeau K., A Akdis C. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–1581. doi: 10.1111/all.14364. - DOI - PMC - PubMed
    1. Soy M., Keser G., Atagündüz P., Tabak F., Atagündüz I., Kayhan S. Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment. Clin. Rheumatol. 2020;39:2085–2094. doi: 10.1007/s10067-020-05190-5. - DOI - PMC - PubMed